Therapeutic drug monitoring of beta-lactam antibiotics in burns patients-a one-year prospective study

Therapeutic Drug Monitoring

Volumn 34, Issue 2, 2012, Pages 160-164

  Patel, Bhavik M ^a,b   Paratz, Jennifer ^a,b   See, Natalie C ^a   Muller, Michael J ^a,b   Rudd, Michael ^a,b   Paterson, David ^a   Briscoe, Scott E ^c   Ungerer, Jacobus ^c   McWhinney, Brett C ^c   Lipman, Jeffrey ^a,b   Roberts, Jason A ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b Centre for Clinical Research   (Australia)

^c ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

beta lactam antibiotics; pharmacodynamics; pharmacokinetics; TDM and dosing

Indexed keywords

AMPICILLIN; BETA LACTAM ANTIBIOTIC; CEFTRIAXONE; DICLOXACILLIN; FLUCLOXACILLIN; MEROPENEM; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BLOOD SAMPLING; BODY SURFACE; BURN; BURN INFECTION; BURN PATIENT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG UTILIZATION; FEMALE; HUMAN; MALE; MINIMUM INHIBITORY CONCENTRATION; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RELIABILITY; RISK ASSESSMENT; STEADY STATE; TREATMENT DURATION;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BETA-LACTAMS; BODY SURFACE AREA; BURNS; CREATININE; DRUG MONITORING; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; TIME FACTORS;

EID: 84863393419     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31824981a6     Document Type: Article

References (14)

1. Fitzwater J, Purdue G, Hunt J, et al. The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma. 2003;54: 959-966. (Pubitemid 36758807)
2. State of Our Public Hospitals in Queensland. Brisbane, Australia: Queensland Health; 2007.
3. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in critically ill patients. Crit Care Med. 2009;37:840-851.
4. Walstad RA, Aandreud L, Thurmann-Nielsen E. Pharmacokinetics and tissue concentrations of Ceftazidime in burn patients. Eur J Clin Pharmacol. 1988;35:543-549. (Pubitemid 18264760)
5. Weinbren MJ. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother. 1999;44:319-327. (Pubitemid 29425682)
6. Ryan DM. Pharmacokinetics of antibiotics in natural and experimental superficial compartments in animals and humans. J Antimicrob Chemother. 1993;31:1-16. (Pubitemid 23193749)
7. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimizing antibiotic dosing in critically ill patients. Clin Pharmacokinet. 2011;50:99-110.
8. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998;26:1-10.
9. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat Rev Microbiol. 2004;2:289-300. (Pubitemid 39490099)
10. Ariano RE, Nyhlen A, Donnelly PJ, et al. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteraemia. Ann Pharmacother. 2005;39:32-38. (Pubitemid 40052375)
11. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T .MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008; 31:345-351.
12. Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36:332-339.
13. McWhinney BC, Wallis SC, Hillister T, et al. Analysis of twelve betalactam antibiotics in human plasma by HPLC with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2010; 878:2039-2043.
14. Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia-special emphasis on unbound pharmacokinetics. J Antimicrob Chemother. 2010;65: 1771-1778.